AgomAb Therapeutics NV
- Last sale
- Nov 12, 2026 · -9.38%
- Market cap
- $214.57M
- 34.17M shares
- Filings
- 51
—
—
——
—
——
—
——
—
——
—
——
—
—- $214.57M
- —
- —
- —
- —
- —
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Common Shares Outstanding
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | 34,167,168 sh | reported |
Biological products, except diagnostic substances
AgomAb Therapeutics NV is the 88th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
LXEOLexeo Therapeutics, Inc.———$240.9MDTILPrecision Biosciences Inc———$224.3MIKTInhibikase Therapeutics, Inc.———$214.6M
AGMBAgomAb Therapeutics NV (this company)———$214.6M
PALIPalisade Bio, Inc.$0.0——$206.2MARTVArtiva Biotherapeutics, Inc.$0.0100.0%—$204.4MCGENCompugen Ltd$72.8M161.1%48.6%$200.5MLIMNLiminatus Pharma, Inc.———$198.1MACOGAlpha Cognition Inc.$10.2M—202.2%$188.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
AgomAb Therapeutics NV · CIK 2020932 · Engraved from SEC EDGAR